Primex Clinical Laboratories INC.

Primex Clinical Laboratories INC. was paid $27.28M by Medicaid between Jan 2018 and Dec 2024, across 190 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 46% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#36 of 561

Median peer was paid$222K

This provider vs. median123×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	355,499	$3.12M
2019	270,496	$2.33M
2020	187,151	$5.54M
2021	279,482	$5.79M
2022	242,620	$6.31M
2023	184,047	$2.77M
2024incomplete	182,563	$1.43M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	46%	217,159	163,791	$12.49M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	7.7%	66,256	60,130	$2.09M
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	7.6%	66,223	60,076	$2.08M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	4.7%	82,378	62,623	$1.29M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	3.0%	27,996	25,349	$823K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	2.9%	45,404	42,337	$799K
84443	Thyroid stimulating hormone (TSH)	2.3%	87,560	84,340	$621K
80061	Lipid panel	2.2%	102,477	99,214	$598K
80053	Comprehensive metabolic panel	2.0%	112,506	108,717	$548K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	1.9%	24,589	22,954	$525K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.8%	143,298	134,520	$484K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.7%	5,600	5,248	$455K

178 more codes

82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.6%	39,560	$439K
83036	Hemoglobin; glycosylated (A1C)	1.5%	97,607	$421K
80055		1.1%	9,368	$294K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	8,707	$244K
86481		<1%	4,029	$238K
86769		<1%	4,575	$183K
86592		<1%	55,609	$173K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	1,019	$165K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	2,486	$141K
88142		<1%	7,551	$124K
81513		<1%	1,199	$119K
84436		<1%	39,144	$110K
84479		<1%	34,504	$93K
86803		<1%	10,573	$89K
84702		<1%	7,567	$82K
87088		<1%	21,093	$79K
86003		<1%	976	$76K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	3,462	$69K
82746		<1%	12,104	$68K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	385	$68K
82607		<1%	14,789	$67K
88141		<1%	5,634	$56K
81001		<1%	45,255	$53K
83655		<1%	6,527	$52K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	1,954	$51K
80164		<1%	7,378	$48K
84439		<1%	14,134	$47K
84153		<1%	9,014	$44K
80074		<1%	1,365	$34K
87184		<1%	11,435	$32K
81401		<1%	47	$31K
82950		<1%	10,062	$30K
82728		<1%	7,758	$29K
82570		<1%	14,100	$26K
84146		<1%	3,776	$26K
87340		<1%	4,911	$25K
82043		<1%	12,574	$24K
83540		<1%	12,378	$23K
83550		<1%	8,836	$23K
87081		<1%	4,582	$22K
82248		<1%	9,855	$19K
82951		<1%	1,820	$18K
80159		<1%	1,785	$17K
86480		<1%	547	$16K
87077		<1%	4,147	$15K
86706		<1%	2,675	$14K
80178		<1%	4,250	$13K
86780		<1%	1,127	$12K
87086	Culture, bacterial; quantitative colony count, urine	<1%	4,127	$12K
G0479	Drug test(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry analyzers utilizing immunoassay, enzyme assay, tof, maldi, ldtd, desi, dart, ghpc, gc mass spectrometry), includes sample validation when performed, per date of service	<1%	252	$11K
86709		<1%	1,861	$10K
86705		<1%	1,787	$9K
80048	Basic metabolic panel (calcium, ionized)	<1%	4,240	$9K
87070		<1%	2,296	$9K
87511		<1%	405	$9K
36415	Collection of venous blood by venipuncture	<1%	20,332	$9K
84550		<1%	14,915	$8K
86235		<1%	333	$8K
84481		<1%	1,990	$8K
87255		<1%	267	$8K
86038		<1%	2,150	$8K
87481		<1%	366	$7K
82274		<1%	569	$7K
82247		<1%	1,717	$6K
84403		<1%	1,061	$6K
87640		<1%	329	$6K
83735		<1%	5,531	$5K
82947		<1%	2,507	$5K
82952		<1%	1,633	$5K
83880		<1%	1,467	$5K
84703		<1%	1,692	$5K
82785		<1%	708	$5K
86708		<1%	788	$5K
83090		<1%	841	$5K
82378		<1%	2,586	$5K
87522	Neg quan hep c or qual rna	<1%	256	$4K
82465		<1%	1,588	$4K
83970		<1%	633	$4K
85610		<1%	4,042	$4K
85651		<1%	7,078	$4K
81025		<1%	2,656	$4K
83001		<1%	458	$4K
86696		<1%	532	$4K
86702		<1%	322	$4K
85730		<1%	2,633	$4K
80076		<1%	1,092	$3K
82977		<1%	2,786	$3K
87338		<1%	461	$3K
82670		<1%	198	$3K
86256		<1%	281	$3K
86787		<1%	335	$3K
86160		<1%	433	$3K
83002		<1%	358	$3K
86376		<1%	764	$3K
82105		<1%	1,171	$3K
86140		<1%	2,037	$3K
83718		<1%	451	$3K
86701		<1%	334	$3K
84100		<1%	3,798	$3K
86431		<1%	1,690	$3K
81015		<1%	1,208	$2K
84402		<1%	245	$2K
84460		<1%	1,129	$2K
88342		<1%	25	$2K
86225		<1%	381	$2K
88312		<1%	113	$2K
83013		<1%	43	$2K
86304		<1%	669	$2K
85018		<1%	1,438	$2K
87177		<1%	285	$2K
83525		<1%	221	$1K
86301		<1%	1,189	$1K
82550		<1%	2,120	$1K
83690		<1%	1,098	$1K
83615		<1%	2,337	$1K
82533		<1%	170	$1K
86141		<1%	1,032	$1K
82150		<1%	594	$1K
82270		<1%	415	$1K
86677		<1%	213	$1K
86695		<1%	243	$1K
87797		<1%	68	$1K
83789		<1%	117	$980.48
87210		<1%	306	$934.38
87510		<1%	72	$896.80
86200		<1%	297	$824.54
82024		<1%	75	$792.54
82652		<1%	54	$757.45
87517		<1%	107	$746.64
84480		<1%	464	$713.63
82784		<1%	124	$706.45
84425		<1%	92	$691.74
80050	General health panel	<1%	233	$660.49
84155		<1%	595	$646.82
84450		<1%	433	$608.43
86762		<1%	177	$593.12
85049		<1%	234	$590.81
82565		<1%	260	$590.53
86063		<1%	336	$578.32
85014		<1%	474	$562.61
87045		<1%	162	$514.85
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	15	$431.40
85048		<1%	259	$413.73
86694		<1%	61	$400.12
82172		<1%	36	$377.58
86704		<1%	89	$362.49
86300		<1%	78	$330.43
80342		<1%	13	$310.50
84165		<1%	96	$277.70
86765		<1%	42	$251.58
84681		<1%	89	$247.34
86901		<1%	221	$241.35
86900		<1%	220	$235.84
82374		<1%	290	$214.29
86850		<1%	164	$210.60
83516		<1%	28	$208.60
83014		<1%	43	$203.61
G0328	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous	<1%	474	$170.47
86735		<1%	25	$167.82
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	31	$158.97
82310		<1%	133	$126.54
83520		<1%	13	$119.86
84295		<1%	133	$117.45
84520		<1%	145	$107.23
84134		<1%	16	$102.68
80156		<1%	27	$91.02
85044		<1%	48	$63.98
80069		<1%	24	$63.20
87634		<1%	14	$61.77
84132		<1%	30	$46.76
84154		<1%	31	$44.82
84478		<1%	20	$33.43
82435		<1%	15	$23.22
83695		<1%	80	$14.03
80320		0%	150	$0.00
87480		0%	15	$0.00
99050		0%	14	$0.00
84075		0%	12	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMALEKIANS, NATALIE (DIRECTOR OF BILLING)